10.3 Monoclonal Antibodies & Biologic Therapies for Severe Asthma

10.3 Monoclonal Antibodies & Biologic Therapies for Severe Asthma

Quick Answer: Biologics are humanized or fully human monoclonal antibodies engineered for patients with severe refractory asthma uncontrolled on Step 5 high-dose ICS-LABA therapy. Six biologics are FDA-approved across distinct molecular targets: omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5Rα with ADCC-mediated eosinophil depletion), dupilumab (anti-IL-4Rα blocking IL-4/IL-13 signaling), and tezepelumab (anti-TSLP upstream alarmin inhibitor). Selection requires biomarker phenotyping—blood eosinophils, FeNO, total IgE, and allergic sensitization—alongside comorbidity profiling.

Approximately 5% to 10% of the asthma population suffers from severe asthma, defined by international consensus (ERS/ATS and GINA) as asthma that requires treatment with high-dose inhaled corticosteroids plus a second controller (and/or systemic corticosteroids) to prevent it from becoming uncontrolled, or that remains uncontrolled despite this therapy. These patients experience disproportionate morbidity, accounting for over 50% of total asthma healthcare costs, frequent emergency department visits, and life-threatening exacerbations.

Biologic therapies have revolutionized severe asthma management by intercepting precise cytokine and alarmin cascades. For the Certified Asthma Educator (AE-C), guiding patients through biologic initiation requires a sophisticated understanding of immunological endotypes, biomarker qualifying criteria, injection safety, anaphylaxis management, and long-term adherence counseling.

---

Immunological Endotypes: Type 2-High vs. Type 2-Low Asthma

Severe asthma is not a single uniform disease but a heterogeneous collection of inflammatory phenotypes driven by two distinct immunological endotypes:

1. Type 2-High (T2-High) Asthma

Characterized by eosinophilic airway inflammation driven by both the adaptive immune system (T-helper 2 [Th2] cells) and the innate immune system (type 2 innate lymphoid cells [ILC2]). When the airway epithelium is damaged by allergens, viruses, or pollutants, it releases epithelial cytokines known as alarmins:

• Thymic Stromal Lymphopoietin (TSLP)
• Interleukin-33 (IL-33)
• Interleukin-25 (IL-25)

These alarmins activate dendritic cells and stimulate both Th2 lymphocytes and ILC2s to synthesize three key Type 2 cytokines:

• Interleukin-4 (IL-4): Drives naive T-cell differentiation into Th2 cells and directs B-cell immunoglobulin class-switching to produce Immunoglobulin E (IgE).
• Interleukin-5 (IL-5): The terminal differentiation factor, activator, and survival cytokine for eosinophils.
• Interleukin-13 (IL-13): Shares receptor subunits with IL-4. Drives goblet cell metaplasia, thick mucus production, bronchial smooth muscle hyperreactivity, and induces inducible nitric oxide synthase (iNOS) in airway epithelial cells, generating exhaled nitric oxide (FeNO).

2. Type 2-Low (Non-T2) Asthma

Characterized by neutrophilic or paucigranulocytic inflammation driven by Th1 and Th17 lymphocytes, interleukin-8 (IL-8), interleukin-17 (IL-17), and interleukin-6 (IL-6). Non-T2 asthma is frequently associated with obesity, cigarette smoking, systemic metabolic syndrome, and smooth muscle intrinsic remodeling. Patients typically exhibit low blood eosinophils (<150 cells/mcL), low FeNO (<20-25 ppb), and an absence of allergic sensitization. Non-T2 asthma responds poorly to corticosteroids and traditional T2-targeted biologics.

                          Inhaled Triggers (Allergens, Viruses, Pollutants)
                                                  │
                                                  ▼
                                       Airway Epithelial Cells
                                                  │
                                                  ▼ Releases "Alarmins"
                                   ┌─────────────────────────────┐
                                   │  TSLP, IL-33, IL-25         │ ◄── [Blocked by Tezepelumab]
                                   └──────────────┬──────────────┘
                                                  │
                        ┌─────────────────────────┴─────────────────────────┐
                        ▼                                                   ▼
                   Th2 Cells                                              ILC2s
                        │                                                   │
                        └─────────────────────────┬─────────────────────────┘
                                                  │
             ┌────────────────────────────────────┼────────────────────────────────────┐
             ▼                                    ▼                                    ▼
       Interleukin-5                       Interleukin-4                       Interleukin-13
             │                                    │                                    │
  ┌──────────┴──────────┐                         └─────────────────┬──────────────────┘
  ▼                     ▼                                           ▼
Anti-IL-5          Anti-IL-5Rα                                  IL-4Rα
(Mepolizumab,     (Benralizumab)                           [Blocked by Dupilumab]
 Reslizumab)            │                                           │
  │                     ▼                                 ┌─────────┴─────────┐
  │                NK-Cell ADCC                           ▼                   ▼
  ▼                     │                              B-Cells:         Airway Epithelium:
Eosinophil         Rapid Complete                     IgE Class           iNOS (FeNO ↑),
Apoptosis        Eosinophil Depletion                  Switching          Mucus Plugs &
                                                          │             Hyperreactivity
                                                          ▼
                                                         IgE
                                                [Blocked by Omalizumab]
                                                          │
                                                          ▼
                                                 Mast Cell/Basophil
                                                    Degranulation

---

The Six Monoclonal Antibodies: Pharmacology & Targets

1. Omalizumab (Xolair) — Anti-IgE

• Molecular Structure & Mechanism: Recombinant humanized IgG1κ monoclonal antibody that selectively binds to the Fc region of circulating free human Immunoglobulin E (IgE). By masking the domain that binds to the high-affinity IgE receptor (FcεRI) on mast cells, basophils, and dendritic cells, omalizumab prevents IgE from cross-linking and triggering degranulation. Furthermore, lowering free IgE downregulates FcεRI receptor expression on effector cells.
• Indications & Age: Moderate to severe persistent allergic asthma in patients aged 6 years and older with a positive skin test or in vitro reactivity to a perennial aeroallergen whose symptoms are inadequately controlled with inhaled corticosteroids.
• Biomarker Eligibility: Baseline serum total IgE between 30 and 700 IU/mL (in adults; up to 1,300 IU/mL in children aged 6 to 11) and body weight (kg) within approved dosing table parameters.
• Dosing & Route: Subcutaneous (SQ) injection every 2 weeks or 4 weeks, determined by a nomogram cross-referencing baseline total IgE and body weight.
• Safety & Boxed Warning: Carries a Boxed Warning for anaphylaxis (occurring in ~0.2% of patients). Anaphylaxis can be delayed, occurring beyond 24 hours after injection. Patients must be prescribed and trained on an epinephrine auto-injector.

2. Mepolizumab (Nucala) — Anti-IL-5

• Mechanism: Humanized IgG1κ mAb that binds with high affinity directly to circulating free Interleukin-5 (IL-5), preventing it from binding to the IL-5 receptor alpha chain on the eosinophil surface. This inhibits eosinophil differentiation in the bone marrow, maturation, and survival.
• Indications & Age: Severe asthma with an eosinophilic phenotype in patients aged 6 years and older.
• Biomarker Eligibility: Blood eosinophil count ≥150 cells/mcL at screening or ≥300 cells/mcL in the prior 12 months.
• Dosing & Route: Fixed subcutaneous dose of 100 mg SQ every 4 weeks in patients aged ≥12 years; 40 mg SQ every 4 weeks in children aged 6 to 11 years. Available in prefilled autoinjector, prefilled syringe, and reconstituted vial.

3. Reslizumab (Cinqair) — Anti-IL-5 (Intravenous)

• Mechanism: Humanized IgG4κ mAb that binds specifically to circulating free IL-5, neutralizing its biological activity.
• Indications & Age: Add-on maintenance for severe asthma with an eosinophilic phenotype in adults aged 18 years and older.
• Biomarker Eligibility: Blood eosinophils ≥400 cells/mcL.
• Dosing & Route: Administered strictly via Intravenous (IV) infusion at a weight-based dose of 3 mg/kg over 20 to 50 minutes once every 4 weeks.
• Boxed Warning: Carries a Boxed Warning for anaphylaxis (observed in 0.3% of clinical trial patients). Must be administered in a healthcare setting equipped to manage life-threatening anaphylaxis, with patients monitored for at least 30 minutes post-infusion.

4. Benralizumab (Fasenra) — Anti-IL-5Rα (ADCC Induction)

• Mechanism: Humanized, afucosylated IgG1κ monoclonal antibody directed against the alpha subunit of the IL-5 receptor (IL-5Rα), which is expressed specifically on human eosinophils and basophils.
  • The Afucosylation Advantage: The complete absence of fucose sugar residues on its Fc domain increases its binding affinity for human FcγRIIIa receptors on Natural Killer (NK) cells by more than 50-fold.
  • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Benralizumab bridges target eosinophils to NK cells. The activated NK cells release perforins and granzymes, inducing rapid apoptosis and near-complete depletion of circulating, bone marrow, and tissue eosinophils within 24 hours of administration.
• Indications & Age: Severe asthma with an eosinophilic phenotype in patients aged 12 years and older.
• Biomarker Eligibility: Blood eosinophils ≥150 to 300 cells/mcL.
• Dosing & Route: 30 mg SQ every 4 weeks for the first 3 doses, then every 8 weeks thereafter via prefilled autoinjector pen or syringe. The 8-week maintenance interval offers significant patient convenience.

5. Dupilumab (Dupixent) — Anti-IL-4Rα

• Mechanism: Fully human IgG4 mAb directed against the IL-4 receptor alpha (IL-4Rα) subunit. Because the IL-4Rα chain is a shared component of both the Type I IL-4 receptor complex (IL-4Rα/γc) and the Type II receptor complex (IL-4Rα/IL-13Rα1), dupilumab simultaneously blocks signaling of both IL-4 and IL-13.
  • Halts B-cell class switching to IgE.
  • Decreases epithelial iNOS activity, causing profound drops in FeNO.
  • Reduces goblet cell hyperplasia, reversing mucus plugging.
  • Suppresses vascular cell adhesion molecule-1 (VCAM-1), halting eosinophil migration into lungs.
• Indications & Age: Moderate to severe asthma characterized by an eosinophilic phenotype OR oral corticosteroid (OCS) dependency, approved for patients aged 6 years and older.
• Biomarker Eligibility: Baseline blood eosinophils ≥150 cells/mcL, OR baseline FeNO ≥25 ppb, OR requirement for maintenance daily oral corticosteroids (regardless of baseline biomarker levels).
• Dosing & Route: Subcutaneous injection every 2 weeks:
  • Standard dose: 400 mg loading dose (two 200 mg injections), then 200 mg SQ every 2 weeks.
  • For patients with oral corticosteroid dependence or comorbid moderate-to-severe atopic dermatitis: 600 mg loading dose (two 300 mg injections), then 300 mg SQ every 2 weeks.
• Special Clinical Consideration: Because dupilumab blocks eosinophil tissue migration (via VCAM-1 inhibition) without halting bone marrow release, a transient, asymptomatic spike in circulating blood eosinophils occurs in ~4% to 10% of patients. Clinicians must monitor for rare hypereosinophilic syndromes or unmasked eosinophilic granulomatosis with polyangiitis (EGPA) during systemic steroid tapering.

6. Tezepelumab (Tezspire) — Anti-TSLP (The Upstream Alarmin Inhibitor)

• Mechanism: Fully human IgG2λ mAb that binds selectively to thymic stromal lymphopoietin (TSLP), an epithelial-derived alarmin released in response to non-specific irritants, viruses, pollutants, and allergens. By blocking TSLP from interacting with its heterodimeric receptor complex (TSLPR/IL-7Rα), tezepelumab acts at the very top of the inflammatory hierarchy, shutting down downstream production of IL-4, IL-5, IL-13, IgE, and non-T2 cytokines.
• Indications & Age: Add-on maintenance for severe asthma in patients aged 12 years and older.
• Biomarker Eligibility (No Phenotypic Restriction): Tezepelumab is the only biologic approved without biomarker restrictions. The landmark NAVIGATOR trial proved it significantly reduces exacerbations and improves FEV1 across both T2-high (high eosinophils/FeNO) and T2-low / non-eosinophilic severe asthma (<150 eosinophils/mcL and low FeNO).
• Dosing & Route: Fixed dose of 210 mg SQ every 4 weeks via prefilled pen or syringe.

---

Comprehensive Biologic Selection Matrix

---

Candidate Phenotyping & Clinical Decision Algorithm

When a patient with confirmed severe asthma fails Step 5 inhaled therapy, the asthma educator and multidisciplinary team follow this systematic phenotyping algorithm:

[Step 1: Confirm Severe Asthma Diagnosis]
  │  • Rule out mimicry (vocal cord dysfunction, bronchiectasis, heart failure, GERD).
  │  • Verify inhaler technique and objectively confirm >80% adherence.
  │  • Eliminate environmental triggers (pets, mold, active/passive smoke).
  ▼
[Step 2: Collect Baseline Biomarkers (Prior to Steroid Escalation)]
  │  • Complete Blood Count (CBC) with differential -> Absolute Eosinophil Count (AEC).
  │  • Fractional Exhaled Nitric Oxide (FeNO).
  │  • Total Serum IgE and specific aeroallergen IgE panel / skin prick testing.
  ▼
[Step 3: Map Biomarker Profiles to Optimal Biologic Mechanism]
  │
  ├─► Allergic Phenotype (High IgE + Perennial Sensitization + Variable Eosinophils) ──► Omalizumab
  │
  ├─► Eosinophilic Phenotype (Blood Eos ≥150-300 cells/mcL) ──► Mepolizumab, Benralizumab, Reslizumab
  │
  ├─► High FeNO (≥25 ppb) OR Maintenance Oral Corticosteroid Dependency ──► Dupilumab
  │
  └─► Low Eosinophils (<150 cells/mcL) AND Low FeNO (<25 ppb) [T2-Low] ──► Tezepelumab

---

Patient Counseling: Self-Administration & Anaphylaxis Preparedness

1. Storage and Preparation Technique:
   • Store biologic prefilled pens/syringes in the refrigerator between 36°F and 46°F (2°C to 8°C) in their original cartons to protect from light. Never freeze or shake.
   • Remove the autoinjector from the refrigerator and allow it to sit at room temperature for 30 to 45 minutes before injection. Administering cold medication causes significant local pain and tissue irritation.
   • Inspect the liquid through the viewing window: it should be clear, colorless to pale yellow, and free of visible particulates.
2. Injection Sites and Technique:
   • Acceptable anatomical sites include the front of the mid-thigh or the lower abdomen (at least 2 inches away from the navel). The outer upper arm may be used if administered by a caregiver.
   • Rotate injection sites with every dose; never inject into skin that is tender, bruised, red, hard, or scarred.
3. Anaphylaxis Education and Epinephrine:
   • Educators must ensure patients receiving omalizumab or reslizumab understand the risk of delayed systemic anaphylaxis. Signs include urticaria (hives), angioedema of the tongue/lips, throat tightness, difficulty swallowing, wheezing, lightheadedness, or hypotension.
   • Ensure the patient carries an unexpired epinephrine auto-injector at all times and knows how to inject it into the anterolateral thigh before calling emergency services (911).
4. Controller Adherence Reassurance:
   • Patients must be explicitly counseled: "Biologics are not rescue inhalers and will not stop an acute attack. You must continue taking your daily inhaled steroid-LABA inhaler exactly as prescribed. Do not stop or reduce your daily inhalers without provider consultation."